NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis $0.61 +0.07 (+13.38%) Closing price 04:00 PM EasternExtended Trading$0.56 -0.06 (-9.00%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Curis Stock (NASDAQ:CRIS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Curis alerts:Sign Up Key Stats Today's Range$0.48▼$0.6150-Day Range$0.38▼$1.1652-Week Range$0.33▼$28.40Volume10.57 million shsAverage Volume12.84 million shsMarket Capitalization$2.52 millionP/E RatioN/ADividend YieldN/APrice Target$43.00Consensus RatingHold Company Overview Curis, Inc. is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on targeted therapies designed to interfere with biological pathways involved in tumor growth and survival. The company’s clinical pipeline has included emavusertib, an oral small-molecule inhibitor of IRAK4 and FLT3 being investigated for certain blood cancers and other malignancies. Curis has also worked with partners to develop cancer drug candidates. Historically, Curis collaborated with Genentech on the development of Erivedge (vismodegib), a Hedgehog pathway inhibitor approved to treat certain cases of advanced basal cell carcinoma. Genentech commercializes the drug.AI Generated. May Contain Errors. Read More Curis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCRIS MarketRank™: 2.894736842105 of 5 starsCuris scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingCuris has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialCuris has a consensus price target of $43.00, representing about 6,899.8% upside from its current price of $0.61.Amount of Analyst CoverageCuris has only been the subject of 2 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($8.05) to ($0.65) per share.Price to Book Value per Share RatioCuris has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.47% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 1.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently increased by 134.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.70 News SentimentCuris has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Curis this week, compared to 3 articles on an average week.Search Interest2 people have searched for CRIS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Curis to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Curis is held by insiders.Percentage Held by Institutions29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRIS Stock News HeadlinesCuris (CRIS) Stock Fair Value Falls After Q3 And Private Placement ReworkNovember 18 at 1:10 PM | finance.yahoo.comCuris Reports $8.1 Million Third-Quarter 2026 Net LossNovember 13, 2026 | quiverquant.comQ$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 18 at 1:00 AM | Profits Run (Ad)Curis (CRIS) Q3 2026 Earnings Call Transcript | The Motley FoolNovember 13, 2026 | fool.comCuris (CRIS) Q3 2026 Earnings Call TranscriptNovember 13, 2026 | finance.yahoo.comCuris, Inc. (CRIS) Q3 2026 Earnings Call TranscriptNovember 12, 2026 | seekingalpha.comCuris Provides Third Quarter 2026 Business UpdateNovember 12, 2026 | prnewswire.comCuris Faces Nasdaq Delisting Risk After Bid-Price DeficiencyNovember 6, 2026 | tipranks.comSee More Headlines CRIS Stock Analysis - Frequently Asked Questions How have CRIS shares performed this year? Curis' stock was trading at $19.7420 at the start of the year. Since then, CRIS shares have decreased by 96.9% and is now trading at $0.6143. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($1.94) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.07. Read the conference call transcript. When did Curis' stock split? Curis's stock reverse split on Friday, September 29th 2023.The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Curis investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings11/12/2026Today11/18/2026EGM 202611/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 7 days, CRIS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees24Year Founded2000Price Target and Rating Average Price Target for Curis$43.00 High Price Target$43.00 Low Price Target$43.00 Potential Upside/Downside+6,899.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($6.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.58 million Net MarginsN/A Pretax Margin-1,893.15% Return on Equity-767.00% Return on Assets-222.98% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.49 Sales & Book Value Annual Sales$9.44 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.62 per share Price / Book0.99Miscellaneous Outstanding Shares4,100,000Free Float4,042,000Market Cap$2.52 million OptionableNo Data Beta3.28 Social Links 7 Energy Stocks to Buy and Hold ForeverOil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.Get This Free Report This page (NASDAQ:CRIS) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.